Haemonetics Corporation has announced its financial results for the second quarter of fiscal 2027, which ended on September 26, 2026. The report, filed on November 5, 2026, reveals a notable increase in both revenue and earnings, underscoring the company's robust performance in the surgical and medical instruments sector.
According to the filing, Haemonetics reported a revenue increase of 9% for the second quarter, amounting to $358 million. Year-to-date, the company achieved a revenue of $697 million, reflecting an 8% increase compared to the previous year. This growth is attributed to strong demand for its products and services in the surgical and medical instruments market.
Additionally, the company reported earnings per diluted share of $1.00 for the second quarter, with adjusted earnings per diluted share at $1.35. Year-to-date earnings per diluted share reached $1.72, with adjusted earnings at $2.49. These figures highlight Haemonetics' ability to enhance profitability alongside revenue growth.
Haemonetics Corporation, incorporated in Massachusetts, operates in the surgical and medical instruments and apparatus industry, classified under SIC code 3841. The company trades on the New York Stock Exchange under the ticker symbol HAE. It is categorized as a large accelerated filer, indicating its significant size and regulatory obligations.
The filing indicates that the financial results were announced through a press release, which is included as Exhibit 99.1 in the filing. This press release serves as a critical communication tool for investors and stakeholders, providing insights into the company's operational performance and strategic direction.
The positive results may impact various stakeholders, including investors, employees, and competitors in the surgical and medical instruments industry. Investors may view the growth as a sign of stability and potential for future returns, while employees could benefit from the company's success through job security and potential bonuses.
Looking ahead, the filing does not specify any immediate next steps or upcoming events related to these financial results. However, the company is expected to continue monitoring market conditions and may provide further updates in future filings.
In conclusion, Haemonetics Corporation's strong financial performance in the second quarter of fiscal 2027 reflects its competitive position in the surgical and medical instruments market. The company's ability to deliver solid revenue growth and profitability may encourage further investment and innovation in the sector.
Read Next
Ronald N. Tutor sells 150,000 shares of Tutor Perini Corp.
Generation Income Properties reports Q3 2026 results
Greenlane Holdings reports Q3 2026 results amid challenges
Permianville Royalty Trust Reports Q3 Financial Results
Cue Biopharma Reports Q3 Results with Financial Insights
Atlantica Inc Reports Q3 Results, Highlights Financial Updates










